CLINICAL TRIALS PROFILE FOR TACHOSIL

All Clinical Trials for TACHOSIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00285623 ↗	Observational Cohort Study of TachoSil (TC-018-IN)	Completed	Nycomed		2005-12-01	The purpose of this study is to collect information, after exposure to TachoSil ®, of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding. In addition, pharmacoeconomic data will be collected.
NCT00293514 ↗	TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)	Completed	Nycomed	Phase 3	2006-02-01	The purpose of this study is to compare the sealing efficacy and safety of TachoSil® (hereafter referred to as TachoSil) versus standard surgical treatment as the secondary management of intra-operative pulmonary air leakage after a lobectomy in subjects with lung malignancies with or without metastases.
NCT00365248 ↗	TachoSil Paediatric Liver Trial (TC-019-IN)	Completed	Nycomed	Phase 3	2005-10-01	The overall objective is to assess the haemostatic efficacy and safety of TachoSil for control of local bleeding in paediatric patients undergoing surgical resection of the liver with our without segmental liver transplantation.
NCT00440401 ↗	TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)	Completed	Nycomed	Phase 4	2007-02-01	To demonstrate efficacy and safety of TachoSil® in cardiovascular surgery
NCT00546169 ↗	Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)	Completed	Nycomed		2007-06-01	- Effectiveness and reliability of TachoSil in cholecystectomy (elective and acute) - Evaluation of TachoSil in laparoscopic cholecystectomy - Risk profile of patient under anticoagulant therapy undergoing acute cholecystectomy - Pharmaco-economic evaluation - Recording of AE's/SAE's Considering the total number of cholecystectomies in Germany (170.000 cases/y), out of them about 75% laparoscopic and 10.000 conversions totally it seems urgent to record data about usage of TachoSil in such procedures. For the time being TachoSil is applied in about 2% of the gall bladder procedures. Aim is to evaluate a possible patient and procedure profile where TachoSil is most beneficial.

Clinical Trial Conditions for TACHOSIL

Condition Name

Condition Name for TACHOSIL
Intervention	Trials
Cervical Cancer	2
Liver Diseases	2
Pulmonary Diseases	1
Intraoperative Bleeding	1

Condition MeSH

Condition MeSH for TACHOSIL
Intervention	Trials
Hemorrhage	5
Liver Diseases	2
Blood Loss, Surgical	2
Uterine Cervical Neoplasms	2

Clinical Trial Locations for TACHOSIL

Trials by Country

Trials by Country for TACHOSIL
Location	Trials
United States	19
Denmark	5
Germany	4
Austria	3
Netherlands	2

Trials by US State

Trials by US State for TACHOSIL
Location	Trials
West Virginia	1
Washington	1
Texas	1
Oregon	1
Ohio	1

Clinical Trial Progress for TACHOSIL

Clinical Trial Phase

Clinical Trial Phase for TACHOSIL
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	6
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TACHOSIL
Clinical Trial Phase	Trials
Completed	13
Recruiting	2
Unknown status	2

Clinical Trial Sponsors for TACHOSIL

Sponsor Name

Sponsor Name for TACHOSIL
Sponsor	Trials
Nycomed	6
Takeda	2
Asan Medical Center	2

Sponsor Type

Sponsor Type for TACHOSIL
Sponsor	Trials
Industry	12
Other	8

Last updated: May 25, 2026

Tachosil (Fibrinogen/Thrombin Hemostat) Clinical Trials Update, Market Analysis, and Forecast (2024-2034)

Tachosil is a topical hemostatic patch (human fibrinogen and human thrombin) used to achieve local hemostasis in surgical settings. Public clinical development after initial commercialization has been limited, with most updates centered on ongoing real-world use, controlled clinical studies supporting indications and health technology assessments, and expanding label coverage in Europe rather than broad, late-stage pipeline expansion. For market projections, demand is driven by conversion from conventional hemostats in elective and minimally invasive surgery, substitution dynamics in wound management, and reimbursement/access in EU hospital formularies.

Because this response requires specific, citable, drug- and filing-level details (trial registries, enrollment status, endpoints, FDA/EMA approvals by date, and quantified historical sales) and those inputs are not provided, producing a complete and accurate clinical trials update and market projection would violate the “no insufficient information” constraint.